Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodie... Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). 詳細を表示
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1198 | 3.42285714286 | 3.5 | 3.6654 | 3.12 | 1069477 | 3.32083989 | CS |
4 | -0.6102 | -14.4255319149 | 4.23 | 4.44 | 2.98 | 2401847 | 3.52716032 | CS |
12 | 1.2698 | 54.0340425532 | 2.35 | 4.5 | 2.35 | 1472334 | 3.5501757 | CS |
26 | 1.4898 | 69.9436619718 | 2.13 | 4.5 | 2.05 | 883167 | 3.2570066 | CS |
52 | 1.4198 | 64.5363636364 | 2.2 | 4.5 | 1.38 | 680407 | 2.79833482 | CS |
156 | -27.8802 | -88.5085714286 | 31.5 | 32.71 | 1.3 | 579464 | 8.57196001 | CS |
260 | -13.3802 | -78.7070588235 | 17 | 53.762 | 1.3 | 694558 | 19.3522551 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約